Latest From BeiGene Ltd.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
China has stepped up its support for the World Health Organization just as the US is ratcheting up its criticism of both the global health body and China, as policy observers watch closely for any signs the tense bilateral relationship may spill over to the health sector.
Drug Discovery Tools
- Drug Discovery Tools
- In Vitro Diagnostics
- Therapeutic Areas
- BeiGene (Beijing) Co. Ltd.
- Parent & Subsidiaries
- BeiGene Ltd.
- Senior Management
John V Oyler, CEO
Howard Liang, PhD, CFO & Chief Strategy Officer
Guillaume Vignon, PhD, SVP, Bus. Dev.
- Contact Info
Phone: 10 851 48500
No. 30 Science Park Rd. Zhong-Guan-Cun
Life Science Pk
Changping District, 102206